Drug intelligence / Profile preview

collagen-PVP + methotrexate

Development stage: Unknown
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous, Oral

Overview

Collagen-PVP + methotrexate is a combination therapy used for the treatment of rheumatoid arthritis. Collagen-PVP is a biodrug made from porcine type I collagen combined with polyvinylpyrrolidone, while methotrexate is a disease-modifying anti-rheumatic drug (DMARD) that acts as an immunosuppressant. Clinical studies have shown that this combination is more efficacious than methotrexate alone, allowing for lower doses of methotrexate while maintaining or improving efficacy. The combination has demonstrated significant improvements in various rheumatoid arthritis metrics including swollen joint count, Ritchie index, morning stiffness, and disease activity scores.

Other names: polymerized-type I collagen + methotrexate

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on collagen-PVP + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on collagen-PVP + methotrexate.

Explore the full profile